Evaluation of Atorvastatin for the Treatment of Patients With Asthma: A Double-Blind Randomized Clinical Trial

Abdollatif Moini, 1* Ghasem Azimi, 2 Abdolhay Farivar 1

1 Department of Internal Medicine, Amir-al-Momenin Hospital, Arak University of Medical Sciences, Arak, Iran
2 Department of Internal Medicine, Mostafa Khomeini Hospital, Shahed Medical University, Tehran, Iran

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Asthma is a global health problem that can severely restrict life activities and can even cause death if not controlled. It affects about 300 million people worldwide, with a mortality rate of about 250,000 annually. 1 Despite the availability of effective treatments, some patients develop a type of asthma that is difficult to manage and relatively insensitive to corticosteroids. Although the cost of asthma control seems high for both the patient and society, the cost of untreated asthma is even higher. 1 As a result of progress in the understanding of asthma pathophysiology, new targets have been identified for its treatment. One of the drug classes that has recently attracted attention is the statins. 2,3

Statins are among the most common medications used in lipid disorders and were originally prescribed to treat cardiovascular diseases 4,5; however, they have more effects than just lowering blood cholesterol. 6-8 The anti-inflammatory and immunomodulatory effects of statins have been widely described. 8-10 They have been shown to decrease serum C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) levels, 10 reduce the expression of cyclooxygenase-2 (COX-2) and other proinflammatory molecules in animal models, 11 directly inhibit the major histocompatibility complex-2 (MHC-2) induction in lymphocyte activation, 9 and inhibit the activation, proliferation, and differentiation of T lymphocytes to T helper 1 cells (Th1). 12-14 Although the exact mechanisms for the various effects of statins are unknown, 15 their use in diseases with an inflammatory basis, including asthma, has been proposed. 16

The anti-inflammatory effects of simvastatin in a rat experimental model of allergic asthma sensitized with ovalbumin were shown for the first time in 2004, 17 and similar results were re-

Purpose: Statins are known as cholesterol-lowering agents, but have been suggested for the treatment of asthma because of their anti-inflammatory effects. In this study, the potential therapeutic effects of atorvastatin were investigated in asthmatic patients. Methods: A total of 62 patients with persistent mild to moderate asthma who presented at asthma clinics of Arak University of Medical Sciences were recruited in a double-blind randomized clinical trial. The asthma clinical control score was assessed based on the standardized Asthma Control Test. Lung volume, i.e., percentage of forced expiratory volume in one second (FEV1%) and percentage of forced vital capacity (FVC%), and peripheral blood eosinophils were also measured. The intervention group was treated with atorvastatin 40 mg per day for 8 weeks, while the control group received a placebo. Asthma controller treatments were not changed. At the beginning and end of the study, serum cholesterol and triglyceride levels were measured to evaluate adherence of the patients to the treatment. Results: The asthma control score did not significantly differ between the intervention and control groups (P=0.06). Difference in FEV1%, FVC%, and blood eosinophil count between the intervention and control groups were not statistically significant (P>0.05). The differences in post-treatment cholesterol and low-density lipoprotein cholesterol levels were significant (P<0.05). Conclusions: Our study shows that atorvastatin is not effective in the treatment of persistent mild to moderate asthma.

Key Words: Asthma; statins; atorvastatin; Asthma Control Test
ported in 2006. In another study, simvastatin was used in patients with mild to moderate asthma, but no anti-inflammatory effect was detected. The findings regarding the effects of fluvastatin, atorvastatin, and other statins in asthma management have been controversial. Several studies using mice sensitized with ovalbumin have suggested that statins may be effective in asthmatic patients, although the results were inconclusive. For this reason, we investigated the effect of atorvastatin for the treatment of asthmatic patients.

MATERIALS AND METHODS

The research protocol was approved by the Scientific Ethics Committee of Arak University of Medical Sciences, and written informed consent was obtained from the volunteers. Patients with mild persistent to moderate persistent asthma (grades 2 and 3 of severity criteria for asthma) aged 18 to 70 years who presented at asthma clinics of Arak University of Medical Sciences from 24 October 2010 to 10 April 2011 were included in this double-blind clinical trial. Exclusion criteria included taking statin drugs at the time of the study, a history of sensitivity to statins, severe asthma leading to hospitalization within a month prior to the beginning of the study, smoking, hepatitis or active liver disease, myopathy or myositis, and pregnancy. A sample size of 31 patients in the control and intervention groups was deemed to be sufficient to determine a 5-degree increase in the Asthma Control Test (ACT) score, based on an alpha of 0.05 and 90% power. Volunteer patients were alternately allocated to the intervention and control groups based on the time of entering the study. A 24-hour phone line was provided to report any side effects of the drug or asthma exacerbation.

All patients completed a standardized ACT questionnaire upon entering the study, followed by a spirometry test (Desktop, Pony FX, Italy). A peripheral blood sample was taken to determine blood eosinophil counts, and serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglyceride (TG) levels. The intervention group was treated using 40-mg atorvastatin tablets (Sobhan Pharmaceutical Company, Iran) once daily for 8 weeks, while the control group received a placebo. The placebo tablets were prepared by the Food and Drug Department of Arak University of Medical Sciences, were composed of starch and were similar to the atorvastatin tablets in size, shape, and color. The drug and placebo tablets were administered to patients by a staff member. Asthma controller treatments were not changed. Improvement in the degree of clinical control of asthma symptoms based on the ACT score was the primary outcome. The improvement in lung volume, which was quantified as the percentage of forced expiratory volume in one second (FEV1%) and the percentage of forced vital capacity (FVC%), and the reduction in the number of peripheral blood eosinophils after atorvastatin treatment compared with placebo were considered secondary outcomes.

Serum cholesterol and TG measurements were used to evaluate adherence to the treatment. Four weeks after treatment initiation, the ACT questionnaire was re-administered, and the patients were visited to assess possible side effects of the drug and evaluate the asthma control level. Finally, after 8 weeks of treatment, the patients completed the ACT questionnaire for the third time, and a spirometry test was performed. A further peripheral blood sample was collected to determine changes in peripheral blood eosinophil counts and serum cholesterol and TG levels. The data were analyzed using the statistical software SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) and charts were plotted using Excel software (Microsoft, USA). Both independent and dependent samples t-tests were used for comparison of the groups and subgroups. Student’s t-test and the chi-squared test were used as appropriate to compare the treatment and the control groups. The significance level was set at \( P < 0.05 \).

RESULTS

A total of 73 patients initially agreed to participate. Eleven voluntarily left the study, and five were excluded due to complications of the disease or asthma exacerbation (Fig. 1). No mortality occurred during the study period. Demographic information of the patients is summarized in Table 1. As shown in Table 2, the improvement in the ACT score was not significantly different between the intervention and control groups (\( P = 0.06 \)). In terms of the secondary outcomes, there were differences in FEV1%, FVC%, and blood eosinophil counts, but the different-

Fig. 1. Flow diagram of patient participation in the study.
Table 1. Demographic information

| Characteristic                  | Control group (n=29) | Intervention group (n=28) |
|--------------------------------|----------------------|---------------------------|
| Female (%)                     | 19 (67.86)           | 15 (51.72)                |
| Age (yr)                       | 39.68±12.69          | 40.00±14.47               |
| Stage 2 asthma                 | 13 (46.43)           | 14 (48.28)                |
| Stage 3 asthma                 | 15 (53.57)           | 15 (51.72)                |
| Height (cm)                    | 168.39±8.71          | 168.59±7.01               |
| Weight (kg)                    | 69.75±12.37          | 70.62±10.65               |
| BMI (kg/m²)                    | 25.11±3.98           | 24.78±3.22                |
| Volunteer data missing         | 6 (8.22)             | 5 (6.85)                  |
| Missing data due to complications | 2 (2.74)           | 3 (4.11)                  |
| ACT score before treatment     | 15.27±4.34           | 16.78±4.11                |
| ACT score after treatment      | 17.93±4.47           | 19.89±3.20                |
| FEV1 before treatment (%)      | 78.66±14.46          | 78.57±13.29               |
| FEV1 after treatment (%)       | 81.82±13.42          | 83.45±10.81               |
| FVC before treatment (%)       | 85.66±13.60          | 94.96±43.71               |
| FVC after treatment (%)        | 89.86±115.7          | 91.89±10.84               |
| Blood eosinophils before treatment | 221.31±134.02      | 244.36±154.48             |
| Blood eosinophils after treatment | 204.52±134.64      | 179.14±117.43             |
| Total cholesterol before treatment (mg/dL) | 204.41±48.24 | 205.71±68.90               |
| Total cholesterol after treatment (mg/dL) | 202.65±48.22 | 162.85±51.23               |
| LDL-C before treatment (mg/dL) | 118.76±41.76        | 118.32±39.82              |
| LDL-C after treatment (mg/dL)  | 117.65±41.23        | 83.39±31.31               |
| HDL-C before treatment (mg/dL) | 49.72±7.71          | 48.71±10.06               |
| HDL-C after treatment (mg/dL)  | 49.27±7.71          | 50.65±10.89               |
| TG before treatment (mg/dL)    | 120.21±42.42        | 121.96±43.17              |
| TG after treatment (mg/dL)     | 120.41±41.48        | 104.25±35.53              |

Values are mean±SD or number (%), as appropriate. BMI, Body mass index; ACT, Asthma Control Test; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.

Table 2. Comparison of measured variables before and after treatment

| Variable                        | Control group | Intervention group | P-value |
|---------------------------------|---------------|--------------------|---------|
| ACT                             | Before treatment | 15.27±4.34 | 17.83±4.47 | 0.000 | 16.78±4.11 | 19.85±3.20 | 0.000 | 0.060 |
| FEV1%                           | Before treatment | 78.65±14.64 | 81.82±13.42 | 0.001 | 78.57±13.29 | 83.46±10.81 | 0.000 | 0.610 |
| FVC%                            | Before treatment | 85.65±13.60 | 89.86±115.7 | 0.001 | 94.96±43.71 | 91.89±10.48 | 0.000 | 0.500 |
| Eosinophil count                | Before treatment | 221.31±134.01 | 204.62±134.64 | 0.008 | 244.35±154.47 | 179.14±117.43 | 0.000 | 0.450 |
| Total cholesterol (mg/dL)       | Before treatment | 204.41±48.24 | 202.65±48.22 | 0.152 | 205.71±68.90 | 162.85±51.23 | 0.000 | 0.004 |
| LDL-C (mg/dL)                   | Before treatment | 118.75±41.75 | 117.85±41.23 | 0.306 | 118.32±39.81 | 83.39±31.31 | 0.000 | 0.001 |
| HDL-C (mg/dL)                   | Before treatment | 49.72±7.77 | 49.27±7.71 | 0.215 | 48.71±10.05 | 50.85±10.89 | 0.016 | 0.530 |
| TG (mg/dL)                      | Before treatment | 120.20±42.42 | 120.41±41.48 | 0.880 | 121.96±43.17 | 104.25±35.53 | 0.000 | 0.120 |

Values are mean±SD or number as a percentage. ACT, Asthma Control Test; FEV1%, percentage of forced expiratory volume in one second; FVC%, percentage of forced vital capacity; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.
DISCUSSION

In this study, our assumption was that statins have unusual anti-inflammatory properties and may be effective in the treatment of asthma, as inflammation plays a central role in its pathogenesis. The primary variable of the study was the standard ACT questionnaire score, which provided a qualitative evaluation. The spirometric change provided a quantitative assessment of lung function, and the change in peripheral blood eosinophil counts was used as an indirect indicator of airway inflammation severity. Blood lipid measurements were used to assess the reliability of the patient’s adherence to the treatment regimen. Our findings showed that atorvastatin was not effective in improving ACT scores or pulmonary volumes, including FEV1 and FVC. Furthermore, the peripheral blood eosinophil count showed no significant change. The significant difference in blood LDL-C and total cholesterol levels between the intervention and control groups indicated that the patients had adhered to the drug regime.

Our results are consistent with those of Menzies and colleagues,19 who used simvastatin for the first time in the treatment of mild to moderate asthma in humans; they were unable to show evidence of an anti-inflammatory effect of simvastatin after 4 weeks of treatment. In another study, the addition of atorvastatin to inhaled corticosteroids resulted in a reduction in the number of macrophages in sputum, but no improvement in the control of asthma symptoms.20

The therapeutic effects of statins were first reported by McKay et al.17 in a mouse sensitized with ovalbumin; simvastatin led to a reduction in inflammatory cells and eosinophilia as well as IL-4 and IL-5 levels in bronchoalveolar lavage (BAL) fluid. A later similar study showed that simvastatin reduced the levels of specific IgE against ovalbumin and the total numbers of inflammatory cells, macrophages, and neutrophils in the BAL fluid of an allergic mouse sensitized with ovalbumin.18 A reduction in allergic inflammation of the airways and inhibition of Th1- and Th2-associated chemokines has also been reported in ovalbumin-sensitized mice.19 Smooth muscle hypersensitivity in response to acetylcholine was selectively reduced in mice treated with lovastatin.20 Pravastatin inhibited systemic sensitivity to allergens, with reduced production of IL-12 and inhibition of antigen presentation in the lungs of mice.21

With regard to human studies, fluvastatin has been shown to inhibit the proliferation of peripheral blood mononuclear cells, decrease the production of IL-5 and IFN-γ, and inhibit Th1 and Th2 cell migration.22 Wachter23 reported a correlation between taking statins and a reduced rate of asthma exacerbation.

One probable reason for the lack of a significant clinical response to statins in our study, as well as in other human studies, is that the therapeutic effects observed in vitro and in mice do not necessarily occur in humans. Alternatively, the effect of statins might have been primarily due to the inhibition of the activity and differentiation of lymphocytes toward the Th1 subtype.12,13,19 However, the effect of statins on Th2 cells, which are the predominant lymphocytes in the pathogenesis of asthma, is inconclusive. Finally, it may be that a favorable clinical response requires a higher drug dosage or a longer period of treatment, or that the variables selected in this study were insufficiently sensitive to show improved asthma control.

As a limitation of this study, we did not have access to more sensitive quantitative methods for evaluating airway hyper-responsiveness and inflammation. Measurements made using a peak flow meter, methacholine challenge test, or quantitative and sensitive CRP assay, or measurements of the number of saliva eosinophils, the fraction of exhaled nitric oxide, or alveolar nitric oxide22 may provide more informative results.

In conclusion, our data indicate that atorvastatin is not effective for the treatment of mild to moderate asthma. More research on the effects of statins on severe asthma is necessary. As statins may exert a therapeutic effect by influencing the remodeling process, we propose the evaluation of patient responses to long-term treatment with statins.

ACKNOWLEDGMENTS

The authors appreciate the assistance of the Research Council of Arak University of Medical Sciences and the staff of Vali-asr and Amir-al-momenin Hospitals. Our best regards to Dr. Rafii for his kind consultations. We express our sincere gratitude to Farzan Institute for Research & Technology for technical assistance. This paper is the result of a professional dissertation.

REFERENCES

1. Bateman ED, Bousquet J, FitzGerald M, Haahleta T, O’Byrne P, Ohta K, Paggiaro P, Pedersen SE, Soto-Quiróz M, Tan W, Wong G. Global initiative for asthma management and prevention (GINA) [Internet]. 2008. Available from: http://www.ginasthma.org.
2. Kikuchi K, Takizawa H. Lung remodeling in asthma: a new target of anti-asthma therapy. Drug Design Reviews - Online 2005;2:129-36. Available from: http://www.citeulike.org/article/115023.
3. Ennis M. New targets for modifying mast cell activation in asthma. Curr Allergy Asthma Rep 2006;6:247-51.
4. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Albert MA, Danielsohn E, Ríñi N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
7. Ridker PM, Ríñi N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
Circulation 1999;100:230-5.

8. Kwak B, Mulhaupt F, Myt S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.

9. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.

10. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53.

11. Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Díaz C, Hernández G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160:49-58.

12. Ghittoni R, Lazzerini PE, Pasini FL, Baldari CT. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm Allergy Drug Targets 2007;6:3-16.

13. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, Fujita T, Toyo-oka T, Kato T. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003;93:948-56.

14. Qi XF, Kim DH, Yoon YS, Li JH, Jin D, Teng YC, Kim SK, Lee KJ. Fluvalastatin inhibits expression of the chemokine MDC/CCL22 in induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line. Br J Pharmacol 2009;157:1441-50.

15. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.

16. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007;13:3622-36.

17. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-8.

18. Kim DY, Ryu SY, Lim JE, Lee YS, Ro YJ. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol 2007;557:76-86.

19. Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119:328-35.

20. Samson KT, Minoguchi K, Tanaka A, Oda N, Yokoe T, Yamamoto Y, Yamamoto M, Ohta S, Adachi M. Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy 2006;36:475-82.

21. Hothersall EJ, Chaudhuri R, McSharry C, Donnelly I, Lafferty J, McMahon AD, Weir CJ, Meiklejohn J, Sattar N, McInnes I, Wood S, Thomson NC. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax 2008;63:1070-5.

22. Wachter K. Statins tied to few hospital visits for asthma. Internal Medicine News. 2009 May 1:26.

23. Imamura M, Okunishi K, Ohtsu H, Nakagome K, Harada H, Tanaka R, Yamamoto K, Dohi M. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 2009;64:44-9.

24. Chiha Y, Sato S, Misawa M. Inhibition of antigen-induced bronchial smooth muscle hyperresponsiveness by lovastatin in mice. J Smooth Muscle Res 2008;44:123-8.

25. Zeki AA, Franzl L, Last J, Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009;180:731-40.

26. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma (NIH publication no. 08-4051). Bethesda, MD: National Heart, Lung, and Blood Institute; 2007 [accessed 2007 Sep 1]. Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.

27. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65.

28. Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/ Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 2005;25:258-63.

29. Pascual RM, Johnson JJ, Peters SP. Asthma: clinical presentation and management. In: Fishman AP, Elias JA, Fishman JA, Gripp MA, editors. Fishman’s pulmonary diseases and disorders. 4th ed. New York: McGraw Hill; 2008. 817-9.